
Pharus Diagnostics is an innovative company focused on conquering cancer through earlier detection, prevention, and management. Utilizing proprietary, state-of-the-art ML/AI technology integrated with enhanced RNA technology and diverse omics data, they aim for pancancer detection via a single blood draw. Their solution offers simple, affordable screening that can be easily integrated into existing health checkup protocols, providing actionable insights to improve clinical decisions and empower patients and doctors. The company's mission is to help individuals live longer, healthier lives by stopping cancer before it occurs and increasing the time people can spend with their loved ones.

Pharus Diagnostics is an innovative company focused on conquering cancer through earlier detection, prevention, and management. Utilizing proprietary, state-of-the-art ML/AI technology integrated with enhanced RNA technology and diverse omics data, they aim for pancancer detection via a single blood draw. Their solution offers simple, affordable screening that can be easily integrated into existing health checkup protocols, providing actionable insights to improve clinical decisions and empower patients and doctors. The company's mission is to help individuals live longer, healthier lives by stopping cancer before it occurs and increasing the time people can spend with their loved ones.
Founded: April 2022
Headquarters: Los Angeles, United States
Product: RNA-based liquid biopsy for pancancer detection using ML/AI
Recent funding: Series A (Jul 2022) led by CK Hutchison
Employee count (reported): Approximately 11-50
Early cancer detection and screening
2022
Biotechnology
11000000
Series A round reported July 2022; amount recorded as 11,000,000 USD on some profiles.
“CK Hutchison Holdings led Series A”